1. Binding of human recombinant mutant soluble ectodomain of FGFR2IIIc to c subtype of FGFRs: implications for anticancer activity
- Author
-
Guanglin Zhang, Yan-qing He, Ge Liu, Zhong Liu, Weiyi He, Jun Li, Yi Wang, Jun Xu, Shu-Shu Zhang, Xuesong Yang, Guo-Hua Cheng, and Ju Wang
- Subjects
0301 basic medicine ,Angiogenesis ,Transplantation, Heterologous ,Mice, Nude ,FGF-2 ,Apoptosis ,Chick Embryo ,Molecular Dynamics Simulation ,Fibroblast growth factor ,Chorioallantoic Membrane ,heterocomplex ,angiogenesis ,03 medical and health sciences ,0302 clinical medicine ,tumor inhibition ,Cell Line, Tumor ,Neoplasms ,Animals ,Humans ,Protein Isoforms ,soluble FGFR2 ,Medicine ,Receptor, Fibroblast Growth Factor, Type 2 ,Binding Sites ,Neovascularization, Pathologic ,business.industry ,Recombinant Proteins ,In vitro ,Chorioallantoic membrane ,HEK293 Cells ,030104 developmental biology ,Oncology ,Ectodomain ,Cell culture ,030220 oncology & carcinogenesis ,Mutation ,Immunology ,MCF-7 Cells ,Cancer research ,Phosphorylation ,Fibroblast Growth Factor 2 ,business ,Protein Binding ,Research Paper - Abstract
// Zhong Liu 1, * , Ge Liu 1, * , Guang-Lin Zhang 1, * , Jun Li 1 , Yan-Qing He 2 , Shu-Shu Zhang 3 , Yi Wang 1 , Wei-Yi He 1 , Guo-Hua Cheng 4 , Xuesong Yang 2 , Jun Xu 3 , Ju Wang 1 1 Institute of Biomedicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Jinan University, Guangzhou 510632, China 2 Key Laboratory for Regenerative Medicine of the Ministry of Education, Division of Histology and Embryology, Medical College, Jinan University, Guangzhou 510632, China 3 Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China 4 College of Pharmacy, Jinan University, Guangzhou 510632, China * These authors contributed equally to this work Correspondence to: Ju Wang, email: wangju1688@163.com Keywords: heterocomplex, FGF-2, soluble FGFR2, tumor inhibition, angiogenesis Received: April 03, 2016 Accepted: August 24, 2016 Published: September 16, 2016 ABSTRACT FGFRs are considered essential targets for cancer therapy. We previously reported that msFGFR2c, a Ser252Trp mutant soluble ectodomain of FGFR2IIIc, inhibited tumor growth by blocking FGF signaling pathway. However, the underlying molecular mechanism is still obscure. In this study, we reported that msFGFR2c but not wild-type soluble ectodomain of FGFR2IIIc (wsFGFR2c) could selectively bind to c subtype of FGFRs in the presence of FGF-2. Thermodynamic analysis demonstrated that msFGFR2c bound to wsFGFR2c in the presence of FGF-2 with a K value of 6.61 × 10 5 M −1 . Molecular dynamics simulations revealed that the mutated residue Trp252 of msFGFR2c preferred a π-π interaction with His254 of wsFGFR2c. Concomitantly, Arg255 of msFGFR2c and Glu250 of wsFGFR2c adjusted their conformations and formed three H-bonds. These two interactions therefore stabilized the final structure of wsFGFR2c and msFGFR2c heterocomplex. In FGFR2IIIc-positive/high FGF-2-secreted BT-549 cells, msFGFR2c significantly inhibited the proliferation and induced apoptosis by the blockage of FGF-2-activated FGFRs phosphorylation, also the growth and angiogenesis of its xenograft tumors implanted in chick embryo chorioallantoic membrane model. While weaker the above inhibitory effects of msFGFR2c were observed on FGFR2IIIc-negative/low FGF-2-secreted MCF-7 and MDA-MB-231 cell lines in vitro and in vivo . Moreover, msFGFR2c significantly inhibited the proliferation of FGFR1IIIc-positive NCI-H1299 lung cancer cells by the suppression of FGF-2-induced FGFR1 activation and suppressed the growth of NCI-H1299 transplanted tumors in nude mice. In sum, msFGFR2c is a potential anti-tumor agent targeting FGFR2c/FGFR1c-positive tumor cells. These findings also provide a molecular basis for msFGFR2c to disrupt the activation of FGF signaling.
- Published
- 2016
- Full Text
- View/download PDF